Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

2.290 -0.120 (-4.98%)
Streaming Delayed Price Updated: 11:57 AM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 252,427
Open 2.430
Bid (Size) 2.290 (3)
Ask (Size) 2.310 (2)
Prev. Close 2.410
Today's Range 2.230 - 2.430
52wk Range 1.260 - 6.860
Shares Outstanding 976,759,524
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adaptimmune Therapeutics: Q2 Earnings Insights
  Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-43.60%
-43.60%
1 Month
+33.14%
+33.14%
3 Month
+61.27%
+61.27%
6 Month
-26.13%
-26.13%
1 Year
-42.03%
-42.03%

More News

Read More
Adaptimmune Reports Second-Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022
Via Newsfile
69 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Adaptimmune Therapeutics's Return On Capital Employed Insights
Via Benzinga
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
Via Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adaptimmune Therapeutics: Q1 Earnings Insights
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Via Benzinga
Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET
Via Benzinga
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Adaptimmune Therapeutics: Q4 Earnings Insights
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For March 14, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Crashing Today
Via The Motley Fool
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Adaptimmune Therapeutics: Q3 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.